Ekso Bionics stock was our first human augmentation recommendation, and it has drifted lower recently.
But the business case for EKSO's growth is very strong.
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
Ekso Bionics stock was our first human augmentation recommendation, and it has drifted lower recently.
But the business case for EKSO's growth is very strong.
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
Ekso Bionics stock was our first human augmentation recommendation, and it has drifted lower recently.
But the business case for EKSO's growth is very strong.
EKSO is crushing its rivals and hitting many milestones...
By Keith Fitz-Gerald, Chief Investment Strategist, Money Map Report -
We've loved EKSO Bionics for some time now. It's revenue has gone up 80% since we first recommended it. Its exports surged 250% in one year.
And Sterne Agee kicked off coverage of the company with a "buy" rating and an initial price target of $1.75 per share.
Here's why EKSO should be your next profit play...